@article{3000229,
    title = "Secondary prevention measures in anaphylaxis patients: Data from the anaphylaxis registry",
    author = "Kraft, M. and Knop, M.P. and Renaudin, J.-M. and Scherer Hofmeier, K. and Pföhler, C. and Bilò, M.B. and Lang, R. and Treudler, R. and Wagner, N. and Spindler, T. and Hourihane, J.O.B. and Maris, I. and Koehli, A. and Bauer, A. and Lange, L. and Müller, S. and Papadopoulos, N.G. and Wedi, B. and Moeser, A. and Ensina, L.F. and Fernandez-Rivas, M. and Cichocka-Jarosz, E. and Christoff, G. and Garcia, B.E. and Poziomkowska-Gęsicka, I. and Cardona, V. and Mustakov, T.B. and Rabe, U. and Mahler, V. and Grabenhenrich, L. and Dölle-Bierke, S. and Worm, M. and The Network for Online Registration of Anaphylaxis (NORA)",
    journal = "Allergy: European Journal of Allergy and Clinical Immunology",
    year = "2020",
    volume = "75",
    number = "4",
    pages = "901-910",
    publisher = "Wiley-Blackwell Publishing Ltd",
    doi = "10.1111/all.14069",
    keywords = "antihistaminic agent;  corticosteroid;  epinephrine;  venom, adult;  adulthood;  aged;  allergy;  anaphylaxis;  Article;  child;  childhood;  consultation;  disease severity;  drug hypersensitivity;  emergency treatment;  female;  food allergy;  gross national product;  human;  immunotherapy;  infant;  latex allergy;  major clinical study;  male;  mastocytosis;  nutritional counseling;  prescription;  priority journal;  protocol compliance;  reimbursement;  secondary prevention;  venom allergy;  anaphylaxis;  Brazil;  Europe;  register, Anaphylaxis;  Brazil;  Epinephrine;  Europe;  Humans;  Registries;  Secondary Prevention",
    abstract = "Background: Patients with a history of anaphylaxis are at risk of future anaphylactic reactions. Thus, secondary prevention measures are recommended for these patients to prevent or attenuate the next reaction. Methods: Data from the Anaphylaxis Registry were analyzed to identify secondary prevention measures offered to patients who experienced anaphylaxis. Our analysis included 7788 cases from 10 European countries and Brazil. Results: The secondary prevention measures offered varied across the elicitors. A remarkable discrepancy was observed between prevention measures offered in specialized allergy centers (84% of patients were prescribed adrenaline autoinjectors following EAACI guidelines) and outside the centers: Here, EAACI guideline adherence was only 37%. In the multivariate analysis, the elicitor of the reaction, age of the patient, mastocytosis as comorbidity, severity of the reaction, and reimbursement/availability of the autoinjector influence physician's decision to prescribe one. Conclusions: Based on the low implementation of guidelines concerning secondary prevention measures outside of specialized allergy centers, our findings highlight the importance of these specialized centers and the requirement of better education for primary healthcare and emergency physicians. © 2019 The Authors. Allergy published by John Wiley & Sons Ltd."
}